GNMSF News and Press, Genmab A/S Dkk From 09/25/18

Fresenius Medical Care ( FMS +1.5% )( OTCPK:FMCQF )( OTCPK:FSMEM ) assumed with Hold rating and €82 price target at Jefferies. More news on: Fresenius Medical Care AG & Co. KGAA, Fresenius Medical Care AG & Co KGaA, Fresenius Medical Care Holdings, Healthcare stocks news, ...

As expected, the European Commission approves Johnson & Johnson (NYSE: JNJ ) unit Janssen Biotech's DARZALEX (daratumumab), combined with Takeda Pharmaceutical's ( OTCPK:TKPYY ) VELCADE (bortezomib), melphalan and prednisone, for the treatment of adult patients with multiple myeloma in...

Genmab A/S (GNMSF) Q2 2018 Earnings Conference Call August 08, 2018, 12:00 ET Executives Jan van de Winkel - Co-Founder, CEO & President David Eatwell - EVP & CFO Analysts James Quigley - JPMorgan Chase & Co. Wimal Kapadia - Sanford C. Bernstein & Co. Pet...

The following slide deck was published by Genmab A/S in conjunction with their 2018 Q2 earnings Read more ...

Genmab ( OTCPK:GNMSF ): Q2 EPS of DKK4.21 More news on: Genmab A/S, Genmab A/S ADR, Earnings news and commentary, Tech stocks news, Read more ...

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Janssen headlines myeloma therapy in Europe Company: Johnson & Johnson ( JNJ ) and G...

Genmab A/S ( OTCPK:GNMSF -20% ) slumps on the news that collaboration partner Johnson & Johnson ( JNJ -1.2% ) has scrapped an early-stage study assessing the combination of DARZALEX (daratumumab) + Roche's TECENTRIQ (atezolizumab) in second-line lung cancer due to lack of efficacy ...

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. AstraZeneca marks a new historic achievement in competitive lung cancer space Company: As...

Verastem ( VSTM +5.1% ) is up on average volume in apparent response to Genmab's ( OTCPK:GNMSF )( OTCPK:GMXAY ) failed late-stage study of Arzerra (ofatumumab) in indolent B-cell non-Hodgkin lymphoma. Ofatumumab, a CD-20-directed monoclonal antibody, is currently approved in the U.S. t...

Genmab A/S ( OTCPK:GNMSF )( OTCPK:GMXAY )  announces that a Phase 3 clinical trial evaluating Arzerra (ofatumumab) plus bendamustine in patients with indolent B-cell non-Hodgkin lymphoma (iNHL) who have not responded to Roche's Rituxan (rituximab) failed to demonstrate a statistically ...